Abstracts Archive - Page 1527 of 2425 - ACR Meeting Abstracts

Abstract Number: 1643 • 2016 ACR/ARHP Annual Meeting
Tofacitinib: Treatment Outcomes in Seropositive Versus Seronegative Patients in a Phase 3 RA Population
Paul Bird¹, Stephen Hall², Peter Nash³, Carol A Connell⁴, Kenneth Kwok⁵, David Witcombe⁶ and Krishan Thirunavukkarasu⁶, ¹University of New South Wales, Sydney, Australia, Sydney, NSW, Australia, ²Cabrini Health and Monash University, Melbourne, VIC, Australia, ³Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Australia, Sydney, NSW, Australia
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This study examined response to treatment with tofacitinib 5 mg or 10…
Abstract Number: 1644 • 2016 ACR/ARHP Annual Meeting
Dose Selection of Filgotinib, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 3 Studies: Exposure-DAS28 and ACR Modeling Approach
Namour Florence¹, Paul Diderichsen², Eugène Cox², Shringi Sharma³ and Chantal Tasset⁴, ¹Galapagos SASU, Romainville, France, ²Quantitative Solutions-Certara, Breda, Netherlands, ³Gilead Sciences, Foster City, CA, ⁴Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor showing good efficacy and safety in Phase 2B studies in rheumatoid arthritis (RA) patients. The…
Abstract Number: 1645 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of ASP5094, an Anti-Alpha-9-Integrin Monoclonal Antibody, Following Single Intravenous Doses in Healthy Subjects
Tianli Wang¹, Christopher Lademacher², Paul Blahunka², Corrie Howieson², Txheng Yang², Tomasz Wojtkowski², Mina Kikuchi² and Robert Townsend², ¹Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, ²Astellas Pharma Global Development, Inc., Northbrook, IL
Background/Purpose: ASP5094 is a recombinant humanized anti-alpha-9 integrin IgG1 monoclonal antibody (mAb) under development for the treatment of rheumatoid arthritis. This first-in-human placebo‑controlled single ascending‑dose…
Abstract Number: 1646 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies
Roy Fleischmann¹, Jürgen Wollenhaupt², Stanley Cohen¹, Michael Weinblatt³, Lisy Wang⁴, Haiyun Fan⁵, John Andrews⁶, Liza Takiya⁵ and Eustratios Bananis⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Brigham and Women’s Hospital, Boston, MA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a post-hoc analysis of the tofacitinib RA long-term extension (LTE) studies,…
Abstract Number: 1647 • 2016 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Staci Abramsky⁵, Min Wang⁵, Chudy Nduaka⁶, Ryan DeMasi⁵ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The objective of this analysis was to report tofacitinib safety and tolerability…
Abstract Number: 1648 • 2016 ACR/ARHP Annual Meeting
Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months
Vibeke Strand¹, Martin J Bergman², Eun Bong Lee³, Yusuf Yazici⁴, Bethanie Wilkinson⁵, Liza Takiya⁶, Gene Wallenstein⁵, Chuanbo Zang⁷ and Eustratios Bananis⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Taylor Hospital, Ridley Park, PA, ³Seoul National University, Seoul, Korea, Republic of, ⁴New York University, Hospital of Joint Diseases, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. RAPID3 (Routine Assessment of Patient [Pt] Index Data 3) is a pooled…
Abstract Number: 1649 • 2016 ACR/ARHP Annual Meeting
Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Eugenio Chamizo Carmona¹, Carmen Carrasco-Cubero², Juan Jose Aznar Sánchez³, Raul Veroz Gonzalez³, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez³ and Lara Chaves Chaparro¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida, Spain
Background/Purpose: The aim of early RA treatment is remission. Intensive treatment with MTX and treat-to-target approach achieve remission in 30-50% patients. Modifiable risk factors, as…
Abstract Number: 1650 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Inhibits Human Naive B Lymphocyte Development and Function in Vitro
Jens Thiel¹, Nils Venhoff², Raquel Lorenzetti³, Bettina Bannert¹, Reinhard Voll⁴, Diego Kyburz⁵ and Marta Rizzi¹, ¹Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, Freiburg, Germany, ²Department of Internal Medicine, Clinic for Rheumatology and Clincal Immunology, Freiburg, Germany, ³Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, 79106, Germany, ⁴Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany, ⁵Department of Biomedicine, Experimental Rheumatology, University of Basel, 4051 Basel, Switzerland
Background/Purpose: B cells are pivotal to the pathogenesis of many autoimmune diseases including rheumatoid arthritis (RA). Tofacitinib, a JAK inhibitor, is effective and safe in…
Abstract Number: 1651 • 2016 ACR/ARHP Annual Meeting
A Case Series on Patients on Tofacitinib in Combination with a Biologic
Nashla Barroso¹ and Daniel E. Furst², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although there have been significant advances in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). patients can experience a lack of or…
Abstract Number: 1652 • 2016 ACR/ARHP Annual Meeting
Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Natasja Stæhr Gudman¹, Pernille Juhl², Christian S. Thudium³, Anne Sofie Siebuhr⁴, Inger Byrjalsen⁵, Morten Asser Karsdal⁴ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular disease, consequent to vascular and endothelial dysfunction, which…
Abstract Number: 1653 • 2016 ACR/ARHP Annual Meeting
Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial
Jon T. Giles¹, Katherine Liao², Nina Paynter³, Alyssa Wohlfahrt⁴, Afshin Zartoshti⁵, Rachel Broderick⁶, Daniel H. Solomon⁷ and Joan Bathon⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ³Medicine, Harvard University, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁶Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁷Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis is associated with an excess cardiovascular disease (CVD) burden. Fewer CVD events associated with specific DMARD therapies have been reported; however, causal…
Abstract Number: 1654 • 2016 ACR/ARHP Annual Meeting
Differential Serum Protein Expression in Groups of Psoriatic Arthritis Patients Characterised By Specific HLA Genotypes and Clinical Features
Musaab Elmamoun¹, Angela McArdle², Muhammad Haroon³, Robert Winchester⁴, Stephen R. Pennington⁵ and Oliver FitzGerald⁶, ¹Rheumatology, St. Vincent's University Hospital, Department of Rheumatology, Dublin 4, Ireland, ²University College Dublin, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland, ⁶St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with diverse clinical and radiographic manifestations. A number of human leukocyte antigen (HLA) alleles have been found…
Abstract Number: 1655 • 2016 ACR/ARHP Annual Meeting
Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients
Pilar Font-Ugalde¹, Carlos Perez-Sanchez¹, Chary Lopez-Pedrera¹, M. Carmen Castro-Villegas², Maria Carmen Abalos-Aguilera³, Patricia Ruiz-Limon³, Nuria Barbarroja¹, Ivan Arias de la Rosa³, Rafaela Ortega-Castro¹, Alejandro Escudero-Contreras³, Eduardo Collantes-Estévez¹ and Yolanda Jiménez-Gómez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: MicroRNAs (miRNAs) are a group of single-stranded non-coding RNAs of 20-25 nucleotides in length that can potentially regulate every aspect of cellular function. Recent…
Abstract Number: 1656 • 2016 ACR/ARHP Annual Meeting
Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis
Yahui Grace Chiu¹, Edward Schwarz², Dongge Li³, Nelson Huertas³, Cristy Bell⁴, Debbie Campbell⁴ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow (BM) is not only the place where osteoclast precursors (OCPs) are derived from, but also the major reservoirs of OCPs. Current data…
Abstract Number: 1657 • 2016 ACR/ARHP Annual Meeting
Soluble Biomarkers May Differentiate Psoriatic Arthritis from Osteoarthritis
Vinod Chandran¹, Anthony V. Perruccio², Suzanne Li³, Fatima Abji⁴, Rajiv Gandhi⁵ and Dafna D Gladman⁶, ¹Medicine, Krembil Research Institute, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University Health Network, Arthritis Program, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: It is often difficult to differentiate psoriatic arthritis (PsA) from osteoarthritis (OA) in clinical practice. To aid clinical diagnosis, we aimed to identify soluble…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].